ArticleIndian journal of surgical oncology2025
Chemoradiotherapy Plus High-dose-rate Intraluminal Brachytherapy Versus Chemoradiotherapy Alone in Locally Advanced Esophageal Carcinoma: A Single Center Experience with Limited Infrastructure.
Article in Indian journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Esophageal carcinoma is one of the most common causes of cancer-related mortality. It usually presents as locally advanced and metastatic disease with poor prognosis. Dysphagia is the most frequent symptom. This is a retrospective study on seventy two patients of locally advanced esophageal carcinoma who had inoperable disease. The patients were divided into two arms- concurrent chemoradiotherapy (CRT) followed by Intraluminal Brachytherapy (ILBT) or CRT alone. In the CRT + ILBT arm (arm A), thirty-six patients received EBRT 50 Gy in 25 fractions at 2 Gy per fraction with concurrent weekly 40 mg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.